证券日报网讯金城医药10月9日在互动平台回答投资者提问时表示，公司正在积极开展市场推广和销售 工作。公司具体经营情况请关注定期报告。 （文章来源：证券日报） ...

Core Viewpoint - The company, Jincheng Pharmaceutical, is currently maintaining a good production capacity utilization rate for glutathione based on market demand and orders [2] Group 1 - The company responded to investor inquiries on October 9, indicating that production is arranged according to market demand and orders [2] - The specific operational situation of the company will be detailed in regular reports [2]

Core Points - The company Jin Cheng Pharmaceutical (300233.SZ) has received a notice from its actual controller and chairman, Zhao Yeqing, regarding an administrative penalty proposed by the China Securities Regulatory Commission (CSRC) for alleged violations of the Securities Law [1] - The proposed penalties include fines totaling 3 million yuan, with Zhao Yeqing responsible for 1.5 million yuan, Wang Zhen for 1.2 million yuan, and Liu Feng for 300,000 yuan [1] - Additionally, Zhao Yeqing is subject to a 4-year market ban, while Wang Zhen faces a 3-year ban, preventing them from engaging in securities business or holding positions in any listed or non-listed public companies during the ban period [1] Summary of Related Sections - **Administrative Penalty Details**: The CSRC has issued a notice indicating that Zhao Yeqing, Wang Zhen, and Liu Feng are suspected of manipulating the securities market, which constitutes a violation of the Securities Law [1] - **Financial Implications**: The total fines amount to 3 million yuan, with specific allocations for each individual involved [1] - **Market Ban Regulations**: The market bans imposed on Zhao Yeqing and Wang Zhen restrict their ability to participate in securities-related activities for the specified duration [1][2]

智通财经APP讯，金城医药(300233.SZ)发布公告，2025年9月30日，公司收到实际控制人、董事长赵叶 青先生的通知，其收到中国证监会重新下发的《行政处罚事先告知书》(处罚字﹝2025﹞69号)(以下简 称"《告知书》")，赵叶青、王震、刘峰涉嫌违反2005年《证券法》第七十七条第一款第一项、第三项 的规定，构成2005年《证券法》第二百零三条所述操纵证券市场的违法行为。《告知书》拟决定如下： 根据《中华人民共和国行政处罚法》第四十五条、第六十三条、第六十四条及《中国证券监督管理委员 会行政处罚听证规则》相关规定，针对上述拟实施的行政处罚，赵叶青先生享有陈述、申辩和要求听证 的权利，提出的事实、理由和证据，经中国证监会复核成立的，中国证监会将予以采纳。 针对本次拟处罚事项，赵叶青先生将依法向中国证监会申请进行陈述、申辩和要求听证。 "一、依据2005年《证券法》第二百零三条的规定，对赵叶青、王震、刘峰处以300万元罚款，其中赵叶 青承担150万元，王震承担120万元，刘峰承担30万元。 二、依据2005年《证券法》第二百三十三条和《证券市场禁入规定》(证监会令第115号)第三条第一 项、第七项和第五条 ...

Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Clobetasol [1] Group 1: Company Information - Clobetasol is a phosphodiesterase 4 (PDE-4) inhibitor, indicated for topical treatment of mild to moderate atopic dermatitis in patients aged 3 months and older [1] - The company has 22 competitors in China with A registration status for Clobetasol raw materials [1] Group 2: Market Data - According to IMS data, the global sales figures for Clobetasol formulations are projected to be $224 million in 2022, $206 million in 2023, and $196 million in 2024 [1] - The consumption of Clobetasol raw materials is expected to be 706.68 kg in 2022, 963.57 kg in 2023, and 1118.43 kg in 2024 [1]

金城医药公告，公司实际控制人、董事长赵叶青涉嫌操纵证券市场违法违规行为，收到中国证监会下发 的《行政处罚事先告知书》。赵叶青、王震、刘峰因违反2005年《证券法》第七十七条第一款第一项、 第三项的规定，涉嫌构成操纵证券市场的违法行为。根据《告知书》，赵叶青拟被处以150万元罚款。 针对本次拟处罚事项，赵叶青将依法向中国证监会申请进行陈述、申辩和要求听证。 ...

Core Viewpoint - Jincheng Pharmaceutical's subsidiary has received approval for the marketing application of Clobetasol, a PDE-4 inhibitor, for treating mild to moderate atopic dermatitis in patients aged 3 months and older [1] Group 1: Company Developments - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received the approval notice from the National Medical Products Administration for the marketing application of Clobetasol [1] - Clobetasol ointment is specifically indicated for local external treatment of atopic dermatitis [1] Group 2: Market Insights - There are currently 22 companies in China with A registration status for Clobetasol raw materials [1] - According to IMS data, the global sales figures for Clobetasol formulations are projected to be $224 million in 2022, $206 million in 2023, and $196 million in 2024 [1] - The consumption of Clobetasol raw materials is expected to be 706.68 kg in 2022, 963.57 kg in 2023, and 1118.43 kg in 2024 [1]

证券代码：300233 证券简称：金城医药 公告编号：2025-066 山东金城医药集团股份有限公司 关于公司实际控制人收到行政处罚事先告知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、基本情况 山东金城医药集团股份有限公司（以下简称"公司"）于 2024 年 8 月 15 日披露了《关于公司实际控制人收到中国证券监督管理委员会立案告知书的公 告》（公告编号：2024-059），公司实际控制人、董事长赵叶青先生收到中国证 券监督管理委员会（以下简称"中国证监会"）的《立案告知书》（证监立案字 〔0392024015〕号），因涉嫌操纵证券市场违法违规行为，根据《中华人民共和 国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对赵叶 青先生立案。 2025 年 3 月 12 日，公司收到赵叶青先生的通知，其收到中国证监会的《行 政处罚事先告知书》（处罚字〔2025〕20 号）。具体内容详见公司在巨潮资讯 网披露的《关于公司实际控制人收到行政处罚事先告知书的公告》（公告编号： 2025-014）。针对前述拟处罚事项，赵叶青先生依法向中国 ...

关于子公司收到化学原料药上市申请批准 证券代码：300233 证券简称：金城医药 公告编号：2025-065 山东金城医药集团股份有限公司 通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"公司"）之全资子公司北京金 城泰尔制药有限公司于近日收到国家药品监督管理局下发的《化学原料药上市申 请批准通知书》（通知书编号：2025YS00871）。现将相关情况公告如下： 一、药品的基本情况 申请事项：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 二、药品相关信息 化学原料药名称：克立硼罗 包装规格：20kg/桶 化学原料药注册标准编号：YBY70202025 生产企业：北京金城泰尔制药有限公司 本次克立硼罗获得《化学原料药上市申请批准通知书》，表明该原料药已符 合国家相关原料药审评技术标准，在符合药品生产质量管理规范要求后，可在国 内市场进行生产销售，将进一步丰富公司原料药产品线，有利于提升公司 ...

Core Viewpoint - Jincheng Pharmaceutical (300233) has completed the basic construction of its Phase II plant and plans to advance gradually based on the progress of plant decoration and product pipeline layout [1] Group 1 - The basic construction of the Phase II plant has been completed [1] - The company will rationally plan and gradually promote based on the decoration progress of the plant and product pipeline layout [1]